Dernières nouvelles pour NovoCure (NASDAQ:NVCR) Stock

NovoCure

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

NovoCure Ltd

AmpliTech Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>, AMPGW))), a leading designer, developer, and manufacturer of advanced signal processing components for satellite, public and private 5G, and other communications networks, including full 5G/6G system design and global distribution of integrated circuit assembly packages and lids, today is proud to announce a landmark achievement: our AmpliTech Inc. division has secured its highest value purchase order in history with the receipt this past Friday of a combined $2 million purchase orders for our proprietary Low Noise Amplifiers from a U.S. Fortune 500 company.
This major win for our core low noise amplifiers division marks the culmination of the most prolific four-month order period in our corporate history, driving our total backlog to nearly $20 million, all slated for delivery within Fiscal Year 2025.

News

Contracts

AMPG

AmpliTech Group Division AmpliTech Inc. Receives Division Purchase Orders Of $2M From A Fortune 500 Company; Total Backlog To Nearly $20M, All Slated For Delivery Within Fiscal Year 2025

U.S. stock futures were slightly lower this morning, with the Dow futures falling around 0.1% on Monday.
Shares of Eagle Financial Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSI#NASDAQ">EFSI</a>) fell sharply in today's pre-market trading after the company released financial <a href="https://www.benzinga.com/quote/efsi">results for the first quarter</a>.
Eagle Financial Services reported quarterly earnings of 62 cents per share, down from 72 cents per share in the year-ago period.
Eagle Financial Services shares dipped 5.8% to $30.51 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>RXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXO#NYSE">RXO</a>) shares dipped 10.7% to $12.01 in pre-market trading. Truist Securities analyst Lucas Servera, on April 24, maintained RXO with a Buy and lowered the price target from $24 to $19.</li>
<li>The ODP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODP#NASDAQ">ODP</a>) declined 9.8% to $12.01 in today's pre-market trading. ODP will announce first quarter financial results before the opening bell on Wednesday, May 7.</li>
<li>Hillman Solutions Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) shares fell 8.3% to $7.03 in pre-market trading.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) tumbled 6.8% to $6.81 in pre-market trading.</li>
<li>Magnera Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAGN#NYSE">MAGN</a>) dipped 6.8% to $13.41 in pre-market trading. Magnera is expected to report second quarter results on May 7.</li>
<li>AleAnna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNA#NASDAQ">ANNA</a>) fell 6.4% to $9.13 in pre-market trading.</li>
<li>Bausch + Lomb Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) fell 2.8% to $13.35 in pre-market trading.</li>
<li>Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) slipped 2.2% to $11.85 in pre-market trading. Delcath Systems will host a conference call on May 8 to discuss results for its first quarter.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) fell 1.5% to $109.34 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45035424/top-3-health-care-stocks-that-may-rocket-higher-in-april">Top 3 Health Care Stocks That May Rocket Higher In April</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

ANNA

BLCO

DCTH

EFSI

HLMN

MAGN

NVDA

OMER

Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Alpha Cognition Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) (the "Company" or "Alpha Cognition") today announced three upcoming presentations at the 2025 Alzheimer's Association International Conference (the "AAIC"), taking place July 27–31, 2025 in Toronto, Canada.
The presentations will highlight clinical studies supporting ZUNVEYL (benzgalantamine), the Company's lead product and a novel galantamine prodrug approved by the FDA in July 2024 and commercially launched in March 2025. The studies demonstrated bioequivalence to galantamine IR and ER and were integral to the NDA submission and approval.

Biotech

General

ACOG

Alpha Cognition To Present ZUNVEYL Clinical Data At 2025 AAIC

Elon Musk's space-based internet service provider, Starlink, could reportedly face delays in its plans to expand into India due to regulatory requirements.
What Happened: India's telecom minister, Jyotiraditya Scindia, reiterated that Musk's company must comply with stringent local regulations if it plans to operate in the country, <a href="https://www.rcrwireless.com/20250425/5g/starlink-india-telecom-minister">according</a> to RCR Wireless on Friday.
"The process is ongoing. The minute they meet all conditions — including setting up gateways in India and registering user terminals locally — we are ready to issue the license," Scindia said.
SpaceX did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
However, Starlink must go through a significant amount of red tape to get its license in India, as the process involves multiple government agencies like the Department of Telecommunications (DoT), the Telecom Regulatory Authority of India (TRAI), and the Indian National Space Promotion and Authorization Center (IN-SPACe).
"It's not only related to DoT, but also to internal security — gateways have to be in India, any user terminal has to be registered in India…the minute they check all the boxes, which I also hope will be soon, the license should be given," Scindia said, reiterating the importance of domestic gateways and user terminals.
Why It Matters: The news comes in as Starlink just added 13 more low-earth orbit satellites to its constellation aboard SpaceX's Falcon 9 rocket. Starlink has a healthy lead in the space-based internet race with its constellation boasting <a href="https://www.benzinga.com/general/space/25/04/44806935/spacex-launches-27th-falcon-9-rocket-from-florida-adds-27-starlink-satellites-to-orbit">over 7,000 satellites</a> and operating in more than 100 countries.
Starlink also recently<a href="https://www.benzinga.com/25/03/44268506/elon-musk-led-spacex-inks-agreements-with-indias-top-telecom-providers-expands-addressable-market-by-over-850-million-users"> signed an agreement</a> with two of India's major telecom providers, Bharati Airtel, as well as billionaire Mukesh Ambani's Jio Platforms Ltd., to provide satellite internet services in the country.&nbsp;
Musk has been eyeing India for a while, and spoke with Indian Prime Minister Narendra Modi recently, where the <a href="https://www.benzinga.com/general/space/25/04/44882314/tesla-ceo-elon-musk-indian-pm-modi-discuss-deeper-tech-ties-amid-model-y-test-run-in-mumbai">two reportedly discussed</a> ‘immense potential' for collaboration in ‘technology and innovation,' among other things.
On the other hand, Amazon.com Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Project Kuiper, Starlink's closest competitor, <a href="https://www.benzinga.com/general/space/25/04/44977151/jeff-bezos-space-internet-ambitions-falter-as-amazons-project-kuiper-struggles-to-increase-satellite-production-amid-launch-delays">faces significant challenges </a>in deploying its low Earth orbit satellites.
Elsewhere, SpaceX is among the ‘frontrunners' to build U.S. President Donald Trump's <a href="https://docs.google.com/document/d/1IAGucq2_2ZpFiUaXA_9zTDUHAjJYXHUzs3VLrbjGGKw/edit">Golden Dome Missile Defense System</a>, along with Peter Thiel's Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>).
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/45029648/tesla-stock-skyrockets-20-following-elon-musks-return-and-shift-from-doge">Tesla Stock Skyrockets 20% Following Elon Musk&#8217;s Return and Shift From DOGE</a></li>
</ul>
Image Via Shutterstock

SPACE

Tech

AMZN

PLTR

Elon Musk's India Ambitions Face Regulatory Hurdles Amid Uncertainty Around Starlink License: Report

ReShape Lifesciences&#xAE; (NASDAQ:<a href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>), the premier physician-led weight loss and metabolic health-solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/241,151, entitled, "Intragastric Device." When issued, the patent will cover claims for an intragastric balloon system, comprising a swallowable capsule with a self-sealing fill valve and a degradable release valve designed to deflate and open the valve around three months after inflation with saline liquid, and configured for natural excretion after deflation, among other claim features. Once issued, the patent will provide protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).

RSLS

Reshape Lifesciences Receives Notice Of Allowance From USPTO For Patent Application Entitled "Intragastric Device"

JP Morgan analyst Pablo Singzon maintains Kinsale Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) with a Neutral and lowers the price target from $402 to $400.

Price Target

Analyst Ratings

KNSL

JP Morgan Maintains Neutral on Kinsale Cap Gr, Lowers Price Target to $400

Politics

OMEX

Odyssey Marine Exploration Confirms Sufficient Operational Funding And Welcomes New Executive Order By Trump Administration

WKHS

Workhorse Completes 2,400 Mile Drive In W56 Electric Step Van

Delcath Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the Company's Investigational New Drug (IND) application for a Phase 2 clinical trial evaluating HEPZATO&#x2122; in combination with standard of care (SOC) for liver-dominant metastatic breast cancer (mBC). With the FDA's review complete, Delcath is now cleared to initiate patient enrollment in the U.S.
The Phase 2 trial will evaluate the safety and efficacy of HEPZATO in combination with SOC versus SOC alone in patients with liver-dominant HER2-negative mBC following the failure of previous treatments. The SOC options will be the physician's choice of eribulin, vinorelbine or capecitabine. Approximately 90 patients will be enrolled in this randomized, controlled trial. The study will take place at more than 20 sites across the United States and Europe, with patient enrollment expected to begin in the fourth quarter of 2025. The trial's primary endpoint, hepatic progression-free survival, is anticipated to be announced by the end of 2028, while results for overall survival, a secondary endpoint, are expected in 2029.
Company management estimates that approximately 7,000 patients annually in the United States are affected by HER2-negative metastatic breast cancer with liver metastases and are candidates for third line treatment. This population includes patients with a significant burden of liver metastases, which are likely to be the primary cause of mortality. By focusing on this demographic, Delcath intends to offer a novel therapeutic option to those patients with limited treatment alternatives.
"This randomized Phase 2 trial marks an important milestone as we expand the clinical investigation of HEPZATO into patients with liver-dominant metastatic breast cancer," said Gerard Michel, Chief Executive Officer of Delcath Systems, Inc. "We are excited to bring new hope to patient populations in indications beyond metastatic uveal melanoma and to further demonstrate the potential of HEPZATO to address unmet needs in oncology. This study underscores our commitment to broadening the applications of HEPZATO and the underlying hepatic delivery system, positioning us as a platform technology that can offer directed treatment options for a variety of liver-dominant cancers."

Delcath Systems Receives FDA Clearance Of IND Application For Phase 2 Clinical Trial Of HEPZATO In Liver-Dominant Metastatic Breast Cancer

CIS with or without Papillary:
<ul>
<li>Oral presentation from QUILT-3.032 study showed 71% complete response rate (N=100), with duration of response ranging up to more than 53 months, in BCG-unresponsive NMIBC CIS with or without papillary disease</li>
<li>Probability of duration of complete response of at least 45 months in the FDA label population (N=77) is 51%, with median duration of complete response of 45.4 months</li>
<li>Cystectomy avoidance rate in responders of 84% at 36 months</li>
<li>Disease-specific overall survival rate of 99% at 36 months</li>
<li>Longest follow-up of BCG-unresponsive CIS patients with unmatched more than 5 years data available (as of July 2024 data cutoff)</li>
</ul>
Papillary without CIS:
<ul>
<li>Disease-free survival rate of 58% at 12 months (primary endpoint) and 52% at 24 months</li>
<li>Cystectomy avoidance rate of 82% at 36 months—unmatched by any product in the field to date</li>
<li>Disease-specific overall survival rate of 96% at 36 months</li>
<li>Supplemental BLA submitted for FDA approval for this indication</li>
</ul>
ImmunityBio, Inc. ((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=https%3A%2F%2Fwww.nasdaq.com%2Fmarket-activity%2Fstocks%2Fibrx&amp;,%20esheet=54244486&amp;,%20newsitemid=20250428844244&amp;,%20lan=en-US&amp;,%20anchor=NASDAQ%3A+IBRX&amp;,%20index=1&amp;,%20NASDAQ:%3Ca%20class=">IBRX</a>), a leading immunotherapy company, today announced positive long-term results from its QUILT-3.032 study of ANKTIVA&#xAE; (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with or without papillary disease. The findings were shared during <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fvimeo.com%2F1079187906%3Fshare%3Dcopy%23t%3D0&amp;esheet=54244486&amp;newsitemid=20250428844244&amp;lan=en-US&amp;anchor=an+oral+presentation&amp;index=2&amp;md5=f41605f50cd65cd1051ab482eaf73421">an oral presentation</a> at the American Urological Association Annual Meeting (AUA 2025) in Las Vegas, April 26-29.

IBRX

ImmunityBio Announces Long-term Results From QUILT-3.032 Study Of ANKTIVA Plus BCG For Treatment Of Adult Patients With BCG-unresponsive NMIBC CIS, With Or Without Papillary Disease

Morgan Stanley analyst Javier Martinez downgrades Adecoagro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>) from Equal-Weight to Underweight and lowers the price target from $13 to $10.

Downgrades

AGRO

Morgan Stanley Downgrades Adecoagro to Underweight, Lowers Price Target to $10

IBM Plans To Invest $150B In America Over The Next Five Years, Including $30B+ Investment In Research And Development To Advance And Continue American Manufacturing Of Mainframe And Quantum Computers

JP Morgan analyst Brian Essex maintains Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) with a Underweight and lowers the price target from $122 to $117.

QLYS

JP Morgan Maintains Underweight on Qualys, Lowers Price Target to $117

Earnings

Earnings Beats

Earnings Misses

BMRC

Bank of Marin Q1 EPS $0.30 Misses $0.32 Estimate, Sales $27.82M Beat $25.79M Estimate

Management

MongoDB Names Mike Berry CFO, Effective May 27, 2025

Morgan Stanley analyst Tejas Savant downgrades Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) from Overweight to Equal-Weight and lowers the price target from $25 to $15.

AVTR

Morgan Stanley Downgrades Avantor to Equal-Weight, Lowers Price Target to $15

JP Morgan analyst Brian Essex maintains Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) with a Overweight and lowers the price target from $53 to $43.

TENB

JP Morgan Maintains Overweight on Tenable Holdings, Lowers Price Target to $43

<h3 class="wp-block-heading">From Fringe to Forefront: The Rise of Mitragynine</h3>
Wellness trends often emerge at the fringes of mainstream attention—passed between friends, spotlighted in boutique retailers, or debated in digital communities. From adaptogenic mushrooms to CBD, the path is familiar: niche adoption turns to broader interest, and eventually, market boom.
Now, a new botanical is following that trajectory: Mitragynine. This naturally occurring alkaloid found in the leaves of Mitragyna speciosa—a tropical tree native to Southeast Asia—is starting to show signs of breaking into the cultural and commercial spotlight. Once relegated to online forums and alternative wellness circles, Mitragynine is now entering the ready-to-drink beverage category, an arena already primed for growth.
<h3 class="wp-block-heading">A Culture Craving Calm</h3>
One of the most telling shifts in consumer behavior over the last five years has been the rise of the "slow wellness" movement. People are no longer chasing overstimulation. Instead, they're seeking clarity without the crash, calm without sedation, and performance without artificiality.
According to a 2024 McKinsey Health report, 76% of consumers now prioritize mental wellness in their daily decisions. That includes beverage choices. Where once energy drinks dominated, today's buyers are exploring functional drinks that align with mood, intention, and long-term wellness.
Mitragynine fits naturally into this narrative. Its mood-balancing, focus-enhancing potential appeals to consumers looking for alternatives to alcohol, synthetic stimulants, and sugar-loaded options. Unlike caffeine-heavy drinks that fuel hustle culture, Mitragynine invites a more centered, aligned approach to productivity and relaxation.
<h3 class="wp-block-heading">Learning from the Botanicals That Came Before</h3>
Mitragynine's current momentum echoes the rise of CBD several years ago. In its early days, CBD experienced scattered adoption, unclear regulatory positioning, and varied product quality. But as interest solidified, the category matured—spurring a wave of investment, innovation, and standardization.
The same dynamics are beginning to unfold with mitragynine. Investors are tracking consumer adoption curves, eyeing brands with clear sourcing, traceability, and scalable operations. And just as CBD's journey paved the way for regulatory frameworks, mitragynine now presents a similar opportunity to bring structure to a still-emerging space.
<h3 class="wp-block-heading">Regulation Isn't a Risk—It's a Catalyst</h3>
Some stakeholders view regulation as a threat. But for operators and investors looking to build responsibly, regulation is a competitive advantage.
When CBD received its first wave of federal guidance, it marked a turning point: brands with transparent practices were rewarded, while opportunists were filtered out. The Mitragynine space is poised for a similar inflection point.
Clear, reasonable guidelines will not only provide consumer safety—they'll also enable retailers, distributors, and investors to engage without fear. That legitimization is what turns a trend into a category.
<h3 class="wp-block-heading">What Investors Should Watch</h3>
So what does "readiness" look like in this space?
It's not just about clever branding. It's about operational infrastructure. Brands that are building vertically integrated supply chains, investing in R&amp;D and formulation expertise, and creating consumer education pathways are positioning themselves to scale sustainably.
We're seeing early signs of capital movement into the category—from angel investors funding beverage startups to CPG veterans entering via joint ventures and partnerships. The next wave will likely bring larger institutional interest, but timing and regulatory positioning will be key.
<h3 class="wp-block-heading">The Road Ahead</h3>
Like all emerging markets, Mitragynine is experiencing its share of skepticism and growing pains. But the parallels with CBD, the rise of mood-forward wellness, and the early retail adoption all point to a category on the cusp of acceleration.
For investors, this is a window—perhaps a brief one—to move early, build responsibly, and shape the narrative around what functional botanicals can offer.
Because this isn't just a plant. It's a paradigm shift in how we think about wellness—and where smart capital goes next.

Cannabis

Opinion

The Next Botanical Poised For Breakout Like CBD

KoBold Metals, the mining startup backed by Bill Gates and Jeff Bezos, is ready for a major expansion into the Democratic Republic of Congo (DRC) – a country with a <a target="_blank" href="https://www.benzinga.com/markets/commodities" rel="noreferrer noopener">vast commodity wealth</a>, including cobalt, copper, and lithium.
"KoBold is committed to significant investments in the DRC, potentially amounting to billions of dollars. Our goal is to harness the country's rich mineral resources responsibly and sustainably," Benjamin Katabuka, the firm's newly appointed Director-General in the DRC, <a target="_blank" href="https://www.ft.com/content/3c5859db-2a46-4111-b823-865dc284c33b" rel="noreferrer noopener">said</a> to The Financial Times.
The United States has recently intensified its interest in securing African mineral resources to counter China's dominance. Massad Boulos, President Donald Trump's Senior Adviser for Africa, confirmed that the U.S. and the DRC have "charted a path forward" for a minerals partnership that could enhance American access to lithium, cobalt, and copper—resources critical for electric vehicles and energy storage.
KoBold Metals has shown keen interest in DRC's <a target="_blank" href="https://www.benzinga.com/25/03/44456007/gates-bezos-backed-startup-makes-move-for-dr-congos-lithium" rel="noreferrer noopener">lithium deposits</a>, which could become one of the largest lithium mines globally if legal disputes are resolved. CEO Gerard Barron presented the goal to "responsibly and economically deliver the world's first commercial-scale nodule project."
However, the DRC remains a difficult jurisdiction. Security concerns, such as the ongoing conflict with the M23 rebels, disrupt mining operations, particularly in the eastern regions. Per recent reports, Blackwater founder Erik Prince might provide an <a target="_blank" href="https://www.benzinga.com/news/global/25/04/44885311/blackwater-founder-reaches-a-security-deal-with-dr-congo" rel="noreferrer noopener">initial security deployment</a> in the Katanga province.
Infrastructure challenges, including unreliable energy supplies, further complicate investment. "It's difficult to do business in the DRC," Katabuka acknowledged.
The DRC is the world's leading cobalt supplier and a major copper producer, two elements indispensable for EV batteries and green technologies. Yet, the country has faced criticism for human rights abuses and environmental concerns regarding its <a target="_blank" href="https://www.npr.org/sections/goatsandsoda/2023/02/01/1152893248/red-cobalt-congo-drc-mining-siddharth-kara" rel="noreferrer noopener">mining practices</a>, which NPR dubbed "modern-day slavery."
KoBold's Machine Prospector uses advanced data modeling and AI to systematically analyze geochemical, geophysical, and geological datasets, allowing faster, <a target="_blank" href="https://www.koboldmetals.com/news/robust-and-ethical-cobalt-supply-for-the-electric-vehicle-revolution/" rel="noreferrer noopener">more accurate identification</a> of mineral prospects without relying solely on manual methods. This approach could enable KoBold to develop new, ethical sources of cobalt that meet rising demand.
So far, the firm has raised over $1 billion, with the latest $537 million round with backers such as Breakthrough Energy Ventures, Equinor, Mitsubishi Corporation, and Standard Investments. The firm's leadership, including founder Josh Goldman, has hinted that KoBold may eventually go public, but for now, it remains privately backed and focused on long-term strategic mineral exploration.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/04/45021300/golds-glitter-fades-what-etf-investors-need-to-know-now" target="_blank" rel="noreferrer noopener">Gold's Glitter Fades? What ETF Investors Need To Know Now</a></li>
</ul>

Emerging Markets

Financing

Commodities

BATT

CARZ

COPX

CPER

Fidelity Electric Vehicles and Future Transportation ETF

FDRV

JJMTF

KoBold Metals Prepares Billions To Develop Ethical Sources Of Critical Metals In DR Congo

JP Morgan analyst Brian Essex maintains Varonis Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) with a Overweight and lowers the price target from $55 to $45.

VRNS

JP Morgan Maintains Overweight on Varonis Systems, Lowers Price Target to $45

Press Releases

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

Novocure to Report First Quarter 2025 Financial Results

Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

Comments

NovoCure

Actualités

Dernières nouvelles pour NovoCure (NASDAQ:NVCR) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL